JP6133297B2 - 試料中の希少標的細胞のサイトメトリー検出のための方法及び組成物 - Google Patents
試料中の希少標的細胞のサイトメトリー検出のための方法及び組成物 Download PDFInfo
- Publication number
- JP6133297B2 JP6133297B2 JP2014529846A JP2014529846A JP6133297B2 JP 6133297 B2 JP6133297 B2 JP 6133297B2 JP 2014529846 A JP2014529846 A JP 2014529846A JP 2014529846 A JP2014529846 A JP 2014529846A JP 6133297 B2 JP6133297 B2 JP 6133297B2
- Authority
- JP
- Japan
- Prior art keywords
- sample
- cells
- circulating tumor
- tumor cells
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims description 100
- 238000001514 detection method Methods 0.000 title description 11
- 239000000203 mixture Substances 0.000 title description 7
- 210000004027 cell Anatomy 0.000 claims description 221
- 230000027455 binding Effects 0.000 claims description 102
- 239000003550 marker Substances 0.000 claims description 48
- 238000004163 cytometry Methods 0.000 claims description 33
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 claims description 28
- 210000004369 blood Anatomy 0.000 claims description 25
- 239000008280 blood Substances 0.000 claims description 25
- 239000012530 fluid Substances 0.000 claims description 23
- 239000000427 antigen Substances 0.000 claims description 22
- 102000036639 antigens Human genes 0.000 claims description 22
- 108091007433 antigens Proteins 0.000 claims description 22
- -1 CD79a Proteins 0.000 claims description 19
- 238000003556 assay Methods 0.000 claims description 19
- 241000282414 Homo sapiens Species 0.000 claims description 14
- 239000012634 fragment Substances 0.000 claims description 13
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims description 12
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims description 12
- 230000008878 coupling Effects 0.000 claims description 12
- 238000010168 coupling process Methods 0.000 claims description 12
- 238000005859 coupling reaction Methods 0.000 claims description 12
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 10
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 10
- 238000007822 cytometric assay Methods 0.000 claims description 10
- 102000011782 Keratins Human genes 0.000 claims description 9
- 108010076876 Keratins Proteins 0.000 claims description 9
- 102100027754 Mast/stem cell growth factor receptor Kit Human genes 0.000 claims description 9
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 8
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 8
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 8
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims description 7
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims description 7
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 7
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 6
- 102100034256 Mucin-1 Human genes 0.000 claims description 6
- 108010008707 Mucin-1 Proteins 0.000 claims description 6
- 239000007850 fluorescent dye Substances 0.000 claims description 6
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims description 5
- 102100035248 Alpha-(1,3)-fucosyltransferase 4 Human genes 0.000 claims description 5
- 102100022749 Aminopeptidase N Human genes 0.000 claims description 5
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 claims description 5
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims description 5
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 5
- 102100028668 C-type lectin domain family 4 member C Human genes 0.000 claims description 5
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims description 5
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims description 5
- 102100033215 DNA nucleotidylexotransferase Human genes 0.000 claims description 5
- 102100031983 Ephrin type-B receptor 4 Human genes 0.000 claims description 5
- 102100021260 Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Human genes 0.000 claims description 5
- 102100035716 Glycophorin-A Human genes 0.000 claims description 5
- 108091005250 Glycophorins Proteins 0.000 claims description 5
- 102100030595 HLA class II histocompatibility antigen gamma chain Human genes 0.000 claims description 5
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 5
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 claims description 5
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims description 5
- 101001022185 Homo sapiens Alpha-(1,3)-fucosyltransferase 4 Proteins 0.000 claims description 5
- 101000757160 Homo sapiens Aminopeptidase N Proteins 0.000 claims description 5
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 claims description 5
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims description 5
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 5
- 101000894906 Homo sapiens Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Proteins 0.000 claims description 5
- 101001082627 Homo sapiens HLA class II histocompatibility antigen gamma chain Proteins 0.000 claims description 5
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 5
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 claims description 5
- 101001078143 Homo sapiens Integrin alpha-IIb Proteins 0.000 claims description 5
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 claims description 5
- 101001015004 Homo sapiens Integrin beta-3 Proteins 0.000 claims description 5
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims description 5
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims description 5
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 claims description 5
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims description 5
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims description 5
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims description 5
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 5
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims description 5
- 101000914496 Homo sapiens T-cell antigen CD7 Proteins 0.000 claims description 5
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 claims description 5
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 claims description 5
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 claims description 5
- 101000835093 Homo sapiens Transferrin receptor protein 1 Proteins 0.000 claims description 5
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims description 5
- 102100022341 Integrin alpha-E Human genes 0.000 claims description 5
- 102100025306 Integrin alpha-IIb Human genes 0.000 claims description 5
- 102100022338 Integrin alpha-M Human genes 0.000 claims description 5
- 102100032999 Integrin beta-3 Human genes 0.000 claims description 5
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 claims description 5
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 claims description 5
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims description 5
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims description 5
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 5
- 102000003729 Neprilysin Human genes 0.000 claims description 5
- 108090000028 Neprilysin Proteins 0.000 claims description 5
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims description 5
- 102100028762 Neuropilin-1 Human genes 0.000 claims description 5
- 102100040120 Prominin-1 Human genes 0.000 claims description 5
- 102100035721 Syndecan-1 Human genes 0.000 claims description 5
- 102100027208 T-cell antigen CD7 Human genes 0.000 claims description 5
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 claims description 5
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims description 5
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims description 5
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 claims description 5
- 102100033725 Tumor necrosis factor receptor superfamily member 16 Human genes 0.000 claims description 5
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims description 5
- 239000008191 permeabilizing agent Substances 0.000 claims description 2
- 102100022019 Pregnancy-specific beta-1-glycoprotein 2 Human genes 0.000 claims 1
- 239000000523 sample Substances 0.000 description 141
- 210000004881 tumor cell Anatomy 0.000 description 21
- 210000000265 leukocyte Anatomy 0.000 description 17
- 238000000684 flow cytometry Methods 0.000 description 15
- 238000004458 analytical method Methods 0.000 description 13
- 239000012114 Alexa Fluor 647 Substances 0.000 description 10
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 10
- WHVNXSBKJGAXKU-UHFFFAOYSA-N Alexa Fluor 532 Chemical compound [H+].[H+].CC1(C)C(C)NC(C(=C2OC3=C(C=4C(C(C(C)N=4)(C)C)=CC3=3)S([O-])(=O)=O)S([O-])(=O)=O)=C1C=C2C=3C(C=C1)=CC=C1C(=O)ON1C(=O)CCC1=O WHVNXSBKJGAXKU-UHFFFAOYSA-N 0.000 description 8
- ZAINTDRBUHCDPZ-UHFFFAOYSA-M Alexa Fluor 546 Chemical compound [H+].[Na+].CC1CC(C)(C)NC(C(=C2OC3=C(C4=NC(C)(C)CC(C)C4=CC3=3)S([O-])(=O)=O)S([O-])(=O)=O)=C1C=C2C=3C(C(=C(Cl)C=1Cl)C(O)=O)=C(Cl)C=1SCC(=O)NCCCCCC(=O)ON1C(=O)CCC1=O ZAINTDRBUHCDPZ-UHFFFAOYSA-M 0.000 description 8
- IGAZHQIYONOHQN-UHFFFAOYSA-N Alexa Fluor 555 Chemical compound C=12C=CC(=N)C(S(O)(=O)=O)=C2OC2=C(S(O)(=O)=O)C(N)=CC=C2C=1C1=CC=C(C(O)=O)C=C1C(O)=O IGAZHQIYONOHQN-UHFFFAOYSA-N 0.000 description 8
- 239000012115 Alexa Fluor 660 Substances 0.000 description 8
- 210000002919 epithelial cell Anatomy 0.000 description 7
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 7
- 239000012116 Alexa Fluor 680 Substances 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- 238000000295 emission spectrum Methods 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 5
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 description 5
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 description 5
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 230000009089 cytolysis Effects 0.000 description 5
- 210000003527 eukaryotic cell Anatomy 0.000 description 5
- 238000003384 imaging method Methods 0.000 description 5
- 230000009870 specific binding Effects 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- CZWUESRDTYLNDE-UHFFFAOYSA-N (2z)-2-[(2e,4e,6e)-7-[1-(5-carboxypentyl)-3,3-dimethyl-5-sulfoindol-1-ium-2-yl]hepta-2,4,6-trienylidene]-1-ethyl-3,3-dimethylindole-5-sulfonate Chemical compound CC1(C)C2=CC(S([O-])(=O)=O)=CC=C2N(CC)\C1=C/C=C/C=C/C=C/C1=[N+](CCCCCC(O)=O)C2=CC=C(S(O)(=O)=O)C=C2C1(C)C CZWUESRDTYLNDE-UHFFFAOYSA-N 0.000 description 4
- LIZDKDDCWIEQIN-UHFFFAOYSA-N 6-[2-[5-(3-ethyl-1,1-dimethyl-6,8-disulfobenzo[e]indol-2-ylidene)penta-1,3-dienyl]-1,1-dimethyl-6,8-disulfobenzo[e]indol-3-ium-3-yl]hexanoate Chemical compound C1=CC2=C(S(O)(=O)=O)C=C(S(O)(=O)=O)C=C2C(C2(C)C)=C1N(CC)\C2=C\C=C\C=C\C1=[N+](CCCCCC([O-])=O)C2=CC=C(C(=CC(=C3)S(O)(=O)=O)S(O)(=O)=O)C3=C2C1(C)C LIZDKDDCWIEQIN-UHFFFAOYSA-N 0.000 description 4
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 4
- 239000012103 Alexa Fluor 488 Substances 0.000 description 4
- 239000012109 Alexa Fluor 568 Substances 0.000 description 4
- LGRNGKUSEZTBMB-UHFFFAOYSA-M C3-indocyanine Chemical compound [I-].CC1(C)C2=CC=CC=C2N(CC)C1=CC=CC1=[N+](CC)C2=CC=CC=C2C1(C)C LGRNGKUSEZTBMB-UHFFFAOYSA-M 0.000 description 4
- 102100022002 CD59 glycoprotein Human genes 0.000 description 4
- 108090000397 Caspase 3 Proteins 0.000 description 4
- 102100029855 Caspase-3 Human genes 0.000 description 4
- 101000897400 Homo sapiens CD59 glycoprotein Proteins 0.000 description 4
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 description 4
- 108010004729 Phycoerythrin Proteins 0.000 description 4
- ZYFVNVRFVHJEIU-UHFFFAOYSA-N PicoGreen Chemical compound CN(C)CCCN(CCCN(C)C)C1=CC(=CC2=[N+](C3=CC=CC=C3S2)C)C2=CC=CC=C2N1C1=CC=CC=C1 ZYFVNVRFVHJEIU-UHFFFAOYSA-N 0.000 description 4
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 101150007302 dntt gene Proteins 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- BRJCLSQFZSHLRL-UHFFFAOYSA-N oregon green 488 Chemical compound OC(=O)C1=CC(C(=O)O)=CC=C1C1=C2C=C(F)C(=O)C=C2OC2=CC(O)=C(F)C=C21 BRJCLSQFZSHLRL-UHFFFAOYSA-N 0.000 description 4
- VYNDHICBIRRPFP-UHFFFAOYSA-N pacific blue Chemical compound FC1=C(O)C(F)=C2OC(=O)C(C(=O)O)=CC2=C1 VYNDHICBIRRPFP-UHFFFAOYSA-N 0.000 description 4
- 210000001236 prokaryotic cell Anatomy 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 4
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 4
- 239000012110 Alexa Fluor 594 Substances 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 210000001789 adipocyte Anatomy 0.000 description 3
- 239000012472 biological sample Substances 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 238000004590 computer program Methods 0.000 description 3
- 230000005284 excitation Effects 0.000 description 3
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 3
- 229910052753 mercury Inorganic materials 0.000 description 3
- 210000000663 muscle cell Anatomy 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000012099 Alexa Fluor family Substances 0.000 description 2
- 108010008886 CAM 5.2 antigen Proteins 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 101000975502 Homo sapiens Keratin, type II cytoskeletal 7 Proteins 0.000 description 2
- 101000975496 Homo sapiens Keratin, type II cytoskeletal 8 Proteins 0.000 description 2
- 102100023974 Keratin, type II cytoskeletal 7 Human genes 0.000 description 2
- 102100023972 Keratin, type II cytoskeletal 8 Human genes 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 2
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- DLBFLQKQABVKGT-UHFFFAOYSA-L lucifer yellow dye Chemical compound [Li+].[Li+].[O-]S(=O)(=O)C1=CC(C(N(C(=O)NN)C2=O)=O)=C3C2=CC(S([O-])(=O)=O)=CC3=C1N DLBFLQKQABVKGT-UHFFFAOYSA-L 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- VNPMDUDIDCXVCH-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-3-(3-piperazin-1-ylpropyl)pyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound O=C(CN1C=C(C(CCCN2CCNCC2)=N1)C1=CN=C(NC2CC3=C(C2)C=CC=C3)N=C1)N1CCC2=C(C1)N=NN2 VNPMDUDIDCXVCH-UHFFFAOYSA-N 0.000 description 1
- ZYPDJSJJXZWZJJ-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-3-piperidin-4-yloxypyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C(=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2)OC1CCNCC1 ZYPDJSJJXZWZJJ-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 101100328884 Caenorhabditis elegans sqt-3 gene Proteins 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241001466804 Carnivora Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 101150084967 EPCAM gene Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 108010008177 Fd immunoglobulins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000975474 Homo sapiens Keratin, type I cytoskeletal 10 Proteins 0.000 description 1
- 101000614627 Homo sapiens Keratin, type I cytoskeletal 13 Proteins 0.000 description 1
- 101000998011 Homo sapiens Keratin, type I cytoskeletal 19 Proteins 0.000 description 1
- 101000994460 Homo sapiens Keratin, type I cytoskeletal 20 Proteins 0.000 description 1
- 101001056466 Homo sapiens Keratin, type II cytoskeletal 4 Proteins 0.000 description 1
- 101000797623 Homo sapiens Protein AMBP Proteins 0.000 description 1
- 241000342334 Human metapneumovirus Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 102100023970 Keratin, type I cytoskeletal 10 Human genes 0.000 description 1
- 102100040487 Keratin, type I cytoskeletal 13 Human genes 0.000 description 1
- 102100033420 Keratin, type I cytoskeletal 19 Human genes 0.000 description 1
- 102100032700 Keratin, type I cytoskeletal 20 Human genes 0.000 description 1
- 102100025758 Keratin, type II cytoskeletal 4 Human genes 0.000 description 1
- 102100025756 Keratin, type II cytoskeletal 5 Human genes 0.000 description 1
- 108010070553 Keratin-5 Proteins 0.000 description 1
- 108010070507 Keratin-7 Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101100501585 Mus musculus Epcam gene Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102100032859 Protein AMBP Human genes 0.000 description 1
- 101100272807 Rattus norvegicus Btg2 gene Proteins 0.000 description 1
- 101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102000005918 Ubiquitin Thiolesterase Human genes 0.000 description 1
- 108010005656 Ubiquitin Thiolesterase Proteins 0.000 description 1
- WLDHEUZGFKACJH-UHFFFAOYSA-K amaranth Chemical compound [Na+].[Na+].[Na+].C12=CC=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(O)=C1N=NC1=CC=C(S([O-])(=O)=O)C2=CC=CC=C12 WLDHEUZGFKACJH-UHFFFAOYSA-K 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- CZPLANDPABRVHX-UHFFFAOYSA-N cascade blue Chemical class C=1C2=CC=CC=C2C(NCC)=CC=1C(C=1C=CC(=CC=1)N(CC)CC)=C1C=CC(=[N+](CC)CC)C=C1 CZPLANDPABRVHX-UHFFFAOYSA-N 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000005266 circulating tumour cell Anatomy 0.000 description 1
- 201000010897 colon adenocarcinoma Diseases 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 229960000956 coumarin Drugs 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 150000004775 coumarins Chemical class 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000018732 detection of tumor cell Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000009830 intercalation Methods 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 238000007885 magnetic separation Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 239000002086 nanomaterial Substances 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
- G01N15/1456—Optical investigation techniques, e.g. flow cytometry without spatial resolution of the texture or inner structure of the particle, e.g. processing of pulse signals
- G01N15/1459—Optical investigation techniques, e.g. flow cytometry without spatial resolution of the texture or inner structure of the particle, e.g. processing of pulse signals the analysis being performed on a sample stream
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/533—Production of labelled immunochemicals with fluorescent label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
- G01N2015/1402—Data analysis by thresholding or gating operations performed on the acquired signals or stored data
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
- G01N2015/1477—Multiparameters
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Zoology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Dispersion Chemistry (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Description
上記の通り、本開示は、試料中の希少標的細胞を検出するためのサイトメトリー方法を提供する。「サイトメトリー方法」という用語は、本明細書において、フローサイトメトリー方法及び/又はイメージングサイトメトリー方法を記載するために使用される。従って、「サイトメトリーアッセイ」とはフローサイトメトリーアッセイ及び/又はイメージングサイトメトリーアッセイを意味し、「サイトメータ」はフローサイトメータ及び/又はイメージングサイトメータを意味することができる。
上記の通り、本開示は、試料中の希少標的細胞を検出するためのサイトメトリー方法を提供する。「希少標的細胞」という用語は、本明細書で使用する場合、試料中に存在するある型の細胞を意味するために使用され、ある型の細胞の数が、試料中の細胞の総数の50.0%未満であり、例えば、40%未満、30%未満、20%未満、10%未満、1%未満、0.1%未満、0.01%未満又は0.001%未満である。ある態様では、細胞試料中、非希少細胞の数が希少標的細胞の数より例えば105 倍以上、106 倍以上、107 倍以上、108 倍以上又は109 倍以上を含む104 倍以上多い。対象とする希少標的細胞型には、原核細胞(例えば細菌細胞又は古細菌細胞)及び真核細胞(例えば神経細胞、筋細胞、上皮細胞(例えば循環腫瘍細胞)などの哺乳類の細胞、幹細胞(例えば造血幹細胞)、希少リンパ球(例えば制御性T細胞)、脂肪細胞など)が含まれるが、これらに限定されない。
本明細書で使用する「試料」及び「細胞試料」という用語は、懸濁液中に1又は複数の別個の細胞を任意の所望の濃度で含有する任意の試料を意味する。例えば、細胞試料は、1ミリリットル当たり1011個以下、1010個以下、109 個以下、108 個以下、107 個以下、106 個以下、105 個以下、104 個以下、103 個以下、500個以下、100個以下、10個以下又は1個の細胞を含有することができる。試料は既知の数の細胞又は未知の数の細胞を含有することができる。好適な細胞には、真核細胞(例えば哺乳類の細胞)及び/又は原核細胞(例えば細菌細胞又は古細菌細胞)が含まれる。
上記の通り、本発明の態様は、希少標的細胞のマーカに特異的に結合する少なくとも第1及び第2の結合部材に試料を接触させるステップを有することができる。本明細書で使用する「結合部材」という用語は、希少標的細胞のマーカに特異的に結合するあらゆる作用物質(例えばタンパク質、小分子など)を意味する。「特異的な結合」、「特異的に結合する」などの用語は、溶液又は反応混合物中での他の分子又は部分と比較してある分子に優先的に結合することを意味する。ある実施形態では、結合部材と結合部材が特異的に結合する希少標的細胞のマーカとの親和性は、これらが互いに特異的に結合して結合複合体になると、Kd (解離定数)10-6M以下、例えば10-7M以下、10-8M以下、例えば10-9M以下、10-10 M以下、10-11 M以下、10-12 M以下、10-13 M以下、10-14 M以下、10-15 M以下を特徴とする。「親和性」とは、結合の強さを意味し、結合親和性の増加がKd の低下と相関関係にある。
本開示の方法は、試料のフローサイトメトリーアッセイを含んでもよい。フローサイトメトリーアッセイの手順は当該技術分野において周知である。例えば、オーメロッド(Ormerod)編,「Flow Cytometry:A Practical Approach」,Oxford Univ.Press,1997年、ジャロチェスキー(Jaroszeski)等編,「Flow Cytometry Protocols,Methods in Molecular Biology」,91号,Humana Press,1997年、「Practical Flow Cytometry」,第3編,Wiley−Liss,1995年、ヴィルゴ(Virgo)等著,「Ann Clin Biochem.Jan」,2012年,49(pt1),17−28、リンデン(Linden)等著,「Semin Throm Hemost.」,2004年10月,30版5号,p.502−11、アリソン(Alison)等著,「J Pathol」,2010年12月,222版4号,p.335−344、及びハービッグ(Herbig)等著,「Crit Rev Ther Drug Carrier Syst.」,2007年,24版,3号,p.203−255を参照されたい。これらの開示は参照によって本明細書に組み込まれる。ある態様では、試料のフローサイトメトリーアッセイは、複数の蛍光色素分子の同時励起及び検出が可能なフローサイトメータ、例えば製造元の指示に従って実質的に使用されるBD Biosciences製のFACSCanto(登録商標)フローサイトメータの使用を含む。本開示の方法は、ホールデン(Holden)等著,「Nature Methods」,2005年,2版,p.773及びヴァレット等著(Valet),「Cytometry」,2004年,59版,p.167−171に記載されているようなイメージサイトメトリーを含んでもよく、これらの開示は参照によって本明細書に組み込まれる。
主題の方法を実施するためのサイトメトリーシステムを更に提供する。サイトメトリーシステムは、下記のようにサイトメトリー試料流体サブシステムを備えてもよい。加えて、サイトメトリーシステムは、サイトメトリー試料流体サブシステムに流体的に連結されたサイトメータを備えている。本開示のシステムは、複数の追加の構成要素、例えばデータ出力デバイス(例えばモニタ、プリンタ及び/又はスピーカ)、データ入力デバイス(例えばインターフェースポート、マウス、キーボードなど)、流体処理構成要素、電源などを備えてもよい。
上記の方法の1又は複数の実施形態を実施するためのキットを更に提供する。主題のキットは、様々な構成要素及び試薬を備えてもよい。場合によっては、キットは、本方法に使用される試薬(例えば上記の通り)と、コンピュータプログラムが格納され、コンピュータにロードされると、コンピュータプログラムがコンピュータを作動させて本明細書に記載のサイトメトリーアッセイを実施するコンピュータ可読媒体と、コンピュータプログラムを取得するためのアドレスを有する物理的な基板とを少なくとも備えている。
主題の方法、組成物、システム及びキットは、試料中の希少標的細胞を検出することが望ましい種々の異なる用途に使用される。
前記希少標的細胞のマーカに特異的に結合する第1及び第2の結合部材に前記試料を接触させるステップと、
前記試料のサイトメトリーアッセイにより、結合した第1及び第2の結合部材を含む細胞の存在を分析して、前記試料中の希少標的細胞を検出するステップと
を有することを特徴とする方法。
前記試料のサイトメトリーアッセイにより、結合した第1、第2及び第3の結合部材を含む細胞の存在を分析して、前記試料中の希少標的細胞を検出するステップと
を更に有することを特徴とする付記1乃至3のいずれか1つに記載の方法。
該希少標的細胞のマーカに特異的に結合する第1及び第2の結合部材
を含むことを特徴とする細胞試料。
該サイトメトリー試料流体サブシステムに流体的に連結されたサイトメータ
を備えていることを特徴とするサイトメトリーシステム。
該サイトメトリー試料流体サブシステムに流体的に連結され、前記試料のアッセイにより、結合した第1及び第2の結合部材を含む細胞の存在を分析して、前記試料中の希少標的細胞を検出するように構成されたサイトメータ
を備えていることを特徴とするサイトメトリーシステム。
前記希少標的細胞のマーカに特異的に結合する第1及び第2の結合部材、及び
前記試料のフローサイトメトリーアッセイにより、結合した第1及び第2の結合部材を含む細胞の存在を分析して、前記試料中の希少標的細胞を検出するための前記第1及び第2の結合部材の使用説明
を備えていることを特徴とするキット。
上記の本開示から理解され得る通り、本開示には多種多様な用途がある。従って、以下の実施例は、本発明を構成して使用する方法の完全な開示及び記載を当業者に提供するために提示されており、本発明者が自身の発明であるとみなすものの範囲を限定するものではなく、以下の実施例は、行われた全ての実験例又は行われた唯一の実験例であることを示すものでもない。当業者は、実質的に同様の結果を得るために変更されるか又は変形されてもよい種々の非臨界パラメータを容易に認識する。従って、以下の実施例は、本発明を構成して使用する方法の完全な開示及び記載を当業者に提供するために提示されており、本発明者が自身の発明であるとみなすものの範囲を限定するものではなく、以下の実施例は、行われた全ての実験例又は行われた唯一の実験例であることを示すものでもない。使用される数値(例えば、量、温度など)に関して正確さを確保するように努力しているが、多少の実験誤差及び偏差は考慮されるべきである。
以下の実施例で使用される一般的な材料及びプロトコルを以下に示す。
正常なドナーの静脈血を、ヘパリンナトリウムを含むBD Vacutainer管に採取した。HT−29腫瘍細胞を、血液試料に濃度(i)10,000HT−29細胞/mL、濃度(ii)1,000HT−29細胞/mL、濃度(iii)100HT−29細胞/mL、又は濃度(iv)0HT−29細胞/mLで添加した。4つの試料の各々について、7.5mLを抜き取り、BD Vacutainer CPT管中でスピンさせWBC部分を分離した。CPT試料調製技術は、溶解及び遠心分離を使用するプロトコルと同様であった(図10A及び図10B)。次いで、WBC分画を固定し、透過処理し、CK−FITC及びCK−Alexa647で60分間染色してFACSで解析した(図3)。
本出願は、米国特許法第119条(e)に基づき、2011年9月6日に出願された米国仮特許出願第61/531575号明細書の出願日の優先権を主張している。その開示は参照によって本明細書に組み込まれる。
Claims (15)
- 試料中の循環腫瘍細胞を検出する方法であって、
前記循環腫瘍細胞の同一のマーカに特異的に結合する、識別可能に標識が付された第1及び第2の結合部材に前記試料を接触させるステップと、
前記試料のサイトメトリーアッセイにより、結合した第1及び第2の結合部材を含む細胞の存在を分析して、前記試料中の前記循環腫瘍細胞を検出するステップと
を有することを特徴とする方法。 - 前記第1及び第2の結合部材は、抗体又は該抗体の抗原結合性フラグメントであることを特徴とする請求項1に記載の方法。
- 前記抗体又は該抗体の抗原結合性フラグメントは、前記マーカの同一のエピトープに結合することを特徴とする請求項2に記載の方法。
- 前記第1及び第2の結合部材に蛍光標識を付すことを特徴とする請求項1に記載の方法。
- 前記第1及び第2の結合部材に標識を直接付すことを特徴とする請求項1に記載の方法。
- 前記試料中の非循環腫瘍細胞に標識を付さないことを特徴とする請求項1に記載の方法。
- 前記試料中の有核細胞を透過処理剤で透過処理するステップを更に有することを特徴とする請求項1に記載の方法。
- 前記マーカはサイトケラチンであることを特徴とする請求項1に記載の方法。
- 前記マーカは、CD1a、CD2、CD3、CD4、CD7、CD8、CD10、CD11b、CD13、CD14、CD15、CD16、CD19、CD20、CD22、CD23、CD25、CD30、CD33、CD34、CD38、CD41、CD45、CD56、CD57、CD61、CD64、CD71、CD74、CD79a、CD103、CD117、CD133、CD138、CD271、CD303、CD304、bcl−2、TdT、FMC7、グリコホリンA、サイトケラチン、EpCAM、EphB4、EGFR、CEA、HER2及びMUC−1から選択されることを特徴とする請求項1に記載の方法。
- 前記試料は全血であることを特徴とする請求項1に記載の方法。
- 前記試料をヒトから得ることを特徴とする請求項1に記載の方法。
- マーカを含む循環腫瘍細胞、及び
該循環腫瘍細胞の同一のマーカに特異的に結合する、識別可能に標識が付された第1及び第2の結合部材
を含むことを特徴とする細胞試料。 - 循環腫瘍細胞を含む試料を、該循環腫瘍細胞の同一のマーカに特異的に結合する、識別可能に標識が付された第1及び第2の結合部材に接触させるように構成され、前記試料中の非循環腫瘍細胞は標識が付されていないサイトメトリー試料流体サブシステム、及び
該サイトメトリー試料流体サブシステムに流体的に連結されたサイトメータ
を備えていることを特徴とするサイトメトリーシステム。 - 循環腫瘍細胞を含む試料を、該循環腫瘍細胞の同一のマーカに特異的に結合する、識別可能に標識が付された第1及び第2の結合部材に接触させるように構成されたサイトメトリー試料流体サブシステム、及び
該サイトメトリー試料流体サブシステムに流体的に連結され、前記試料のアッセイにより、結合した第1及び第2の結合部材を含む細胞の存在を分析して、前記試料中の前記循環腫瘍細胞を検出するように構成されたサイトメータ
を備えていることを特徴とするサイトメトリーシステム。 - 試料中の循環腫瘍細胞を特定するためのキットであって、
前記循環腫瘍細胞の同一のマーカに特異的に結合する、識別可能に標識が付された第1及び第2の結合部材、及び
前記試料のサイトメトリーアッセイにより、結合した第1及び第2の結合部材を含む細胞の存在を分析して、前記試料中の前記循環腫瘍細胞を検出するための前記第1及び第2の結合部材の使用説明
を備えていることを特徴とするキット。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161531575P | 2011-09-06 | 2011-09-06 | |
US61/531,575 | 2011-09-06 | ||
PCT/US2012/053933 WO2013036620A1 (en) | 2011-09-06 | 2012-09-06 | Methods and compositions for cytometric detection of rare target cells in a sample |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2014529078A JP2014529078A (ja) | 2014-10-30 |
JP6133297B2 true JP6133297B2 (ja) | 2017-05-24 |
Family
ID=47832549
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014529846A Active JP6133297B2 (ja) | 2011-09-06 | 2012-09-06 | 試料中の希少標的細胞のサイトメトリー検出のための方法及び組成物 |
Country Status (6)
Country | Link |
---|---|
US (1) | US9535065B2 (ja) |
EP (1) | EP2753924B1 (ja) |
JP (1) | JP6133297B2 (ja) |
CN (1) | CN103842813B (ja) |
ES (1) | ES2930651T3 (ja) |
WO (1) | WO2013036620A1 (ja) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2726870B1 (en) | 2011-06-29 | 2018-10-03 | Academia Sinica | The capture, purification and release of biological substance using a surface coating |
US20150233932A1 (en) * | 2013-02-19 | 2015-08-20 | Ching-Ping Tseng | Methods, Systems, and Compositions for Enrichment of Rare Cells |
WO2015153816A2 (en) | 2014-04-01 | 2015-10-08 | Academia Sinica | Methods and systems for cancer diagnosis and prognosis |
EP2998026B1 (en) | 2014-08-26 | 2024-01-17 | Academia Sinica | Collector architecture layout design |
US10107726B2 (en) | 2016-03-16 | 2018-10-23 | Cellmax, Ltd. | Collection of suspended cells using a transferable membrane |
CN108956431B (zh) * | 2018-08-09 | 2021-04-30 | 苏州叠代生物科技有限公司 | 一种单采血小板制品中残留细胞的检测方法 |
CN111089967B (zh) * | 2020-03-25 | 2020-06-26 | 中南大学湘雅二医院 | 红斑狼疮分型的皮肤组织免疫细胞原位检测试剂盒的应用 |
LU500787B1 (en) | 2021-10-26 | 2023-04-27 | Univ Hamburg Eppendorf Uke | Isolation and detection of cdcp1 positive circulating tumor cells |
LU501430B1 (en) | 2022-02-09 | 2023-08-09 | Univ Hamburg Eppendorf Uke | Enrichment, detection and characterization of circulating tumor cells with susd2 and enpp1 |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5945281A (en) | 1996-02-02 | 1999-08-31 | Becton, Dickinson And Company | Method and apparatus for determining an analyte from a sample fluid |
US20010018192A1 (en) * | 1998-02-12 | 2001-08-30 | Terstappen Leon W.M.M. | Labeled cells for use as an internal functional control in rare cell detection assays |
BR9907852A (pt) * | 1998-02-12 | 2000-10-24 | Immunivest Corp | Processos para detectar e enumerar células raras e cancerosas em uma população celular mista, para diagnosticar câncer de estágio precoce em um paciente de teste, para determinar a probabilidade de recorrência de câncer em um paciente humano anteriormente tratado de câncer, para distinguir um carcinoma confinado ao órgão de um carcinoma com propriedades metastáticas, para acompanhar a situação de remissão em um paciente humano com câncer que passa pelo tratamento de terapia contra o câncer e para aumentar quantidades de células epiteliais circulantes em uma amostra de sangue, partìcula magnética revestida, composição, conjuntos de teste para avaliar uma amostra de paciente quanto a presença de células raras circulantes, quanto a presença de células de tumor circulantes, quanto a presença de células de câncer de mama circulantes, quanto a presença de células de câncer de próstata circulantes, quanto a presença de células de câncer de cólon circulantes, quanto a presença de células de câncer de bexiga circulantes e para monitorar um paciente quanto a recorrência de câncer, e, fração de sangue periférico enriquecido quanto a células neoplásticas circulantes |
US6254830B1 (en) | 1999-11-05 | 2001-07-03 | The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations | Magnetic focusing immunosensor for the detection of pathogens |
US6645777B1 (en) | 1999-11-05 | 2003-11-11 | The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantation | Tapered tubular optical waveguide probe for magnetic focusing immunosensors |
DE60142691D1 (de) * | 2000-09-09 | 2010-09-09 | Univ New York State Res Found | Verfahren und zusammensetzungen zur isolierung von metastatischen krebszellen und anwendung zur messung des metastatischen potentials eines krebses |
SE522801C2 (sv) | 2001-03-09 | 2004-03-09 | Erysave Ab | Anordning för att separera suspenderade partiklar från en fluid med ultraljud samt metod för sådan separering |
WO2003067210A2 (en) * | 2001-07-10 | 2003-08-14 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for detecting the activation state of the multiple proteins in single cells |
US7863012B2 (en) | 2004-02-17 | 2011-01-04 | Veridex, Llc | Analysis of circulating tumor cells, fragments, and debris |
EP1564554A1 (en) * | 2004-02-12 | 2005-08-17 | Pepscan Systems B.V. | Method for the detection of early B cell populations in vaccine development |
US20050266503A1 (en) * | 2004-05-24 | 2005-12-01 | Esoterix, Inc. | Simultaneous assay of target and target-drug binding |
US7803523B2 (en) | 2004-08-27 | 2010-09-28 | University Health Network | Whole blood preparation for cytometric analysis of cell signaling pathways |
US7842465B2 (en) * | 2006-01-17 | 2010-11-30 | Palo Alto Research Center Incorporated | Immunocytostaining methods for enhanced dye ratio discrimination in rare event detection |
MX2008013332A (es) * | 2006-04-18 | 2008-11-10 | Wellstat Biologics Corp | Deteccion de proteinas de celulas neoplasicas circulantes. |
EP2027470B1 (en) * | 2006-06-02 | 2012-11-21 | Pfizer Products Inc. | Circulating tumor cell assay |
US20080057505A1 (en) | 2006-07-14 | 2008-03-06 | Ping Lin | Methods and compositions for detecting rare cells from a biological sample |
WO2008008515A2 (en) * | 2006-07-14 | 2008-01-17 | Aviva Biosciences Corporation | Methods and compositions for detecting rare cells from a biological sample |
US8524493B2 (en) * | 2006-09-07 | 2013-09-03 | Centre Hospitalier Universitaire De Montpellier | Released cytokeratins as markers for epithelial cells |
JP2010509570A (ja) * | 2006-11-03 | 2010-03-25 | パーデュー・リサーチ・ファウンデーション | エクスビボフローサイトメトリーの方法および装置 |
US8841135B2 (en) | 2007-06-20 | 2014-09-23 | University Of Washington | Biochip for high-throughput screening of circulating tumor cells |
US20090061456A1 (en) | 2007-08-30 | 2009-03-05 | Allard William J | Method for predicting progression free and overall survival at each follow-up time point during therapy of metastatic breast cancer patients using circulating tumor cells |
WO2009064789A2 (en) | 2007-11-15 | 2009-05-22 | The Johns Hopkins University | Methods for detecting and monitoring circulating cancer stem cells |
CN101251536A (zh) * | 2008-04-01 | 2008-08-27 | 中国烟草总公司郑州烟草研究院 | 评价卷烟烟气毒性的小鼠体内微核分析检测方法 |
BRPI0914734A2 (pt) * | 2008-06-26 | 2015-10-20 | Dana Farber Cancer Inst Inc | assinaturas e determinantes associados com metástase e métodos de uso dos mesmos |
DK2334703T3 (en) * | 2008-09-17 | 2015-10-05 | Innate Pharma | Configurations and methods for detection of tlr3 |
-
2012
- 2012-09-06 US US14/237,856 patent/US9535065B2/en active Active
- 2012-09-06 WO PCT/US2012/053933 patent/WO2013036620A1/en active Application Filing
- 2012-09-06 CN CN201280043030.XA patent/CN103842813B/zh active Active
- 2012-09-06 JP JP2014529846A patent/JP6133297B2/ja active Active
- 2012-09-06 ES ES12830820T patent/ES2930651T3/es active Active
- 2012-09-06 EP EP12830820.2A patent/EP2753924B1/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP2014529078A (ja) | 2014-10-30 |
EP2753924A1 (en) | 2014-07-16 |
ES2930651T3 (es) | 2022-12-20 |
CN103842813A (zh) | 2014-06-04 |
US20140242610A1 (en) | 2014-08-28 |
US9535065B2 (en) | 2017-01-03 |
CN103842813B (zh) | 2018-04-17 |
EP2753924A4 (en) | 2015-04-22 |
EP2753924B1 (en) | 2022-10-26 |
WO2013036620A1 (en) | 2013-03-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6133297B2 (ja) | 試料中の希少標的細胞のサイトメトリー検出のための方法及び組成物 | |
Kimoto et al. | Further development of the rat Pig‐a mutation assay: Measuring rat Pig‐a mutant bone marrow erythroids and a high throughput assay for mutant peripheral blood reticulocytes | |
KR101716555B1 (ko) | 포유동물 대상체에서 5t4-양성 순환 종양 세포를 검출하는 방법 및 5t4-양성 암을 진단하는 방법 | |
Dent et al. | High‐resolution imaging for the detection and characterisation of circulating tumour cells from patients with oesophageal, hepatocellular, thyroid and ovarian cancers | |
Kraan et al. | Flow cytometric immunophenotyping of cerebrospinal fluid | |
JPH02103464A (ja) | サンプル中の損傷細胞及びインタクト細胞を識別するための方法 | |
EP2833149B1 (en) | Method for detecting degree of malignancy of circulating tumor cell unit, and kit for same | |
Cherian et al. | Flow cytometric monitoring for residual disease in B lymphoblastic leukemia post T cell engaging targeted therapies | |
Soh et al. | Methodological considerations for the high sensitivity detection of multiple myeloma measurable residual disease | |
Bouriche et al. | Detection of minimal residual disease in B cell acute lymphoblastic leukemia using an eight‐color tube with dried antibody reagents | |
Joshi et al. | Enrichment of circulating melanoma cells (CMCs) using negative selection from patients with metastatic melanoma | |
Bayly et al. | Validation of a modified pre‐lysis sample preparation technique for flow cytometric minimal residual disease assessment in multiple myeloma, chronic lymphocytic leukemia, and B‐non Hodgkin lymphoma | |
Kwok et al. | High-dimensional multi-pass flow cytometry via spectrally encoded cellular barcoding | |
Dey | Diagnostic flow cytometry in cytology | |
Sanchez-Pino | Detection of circulating and tissue myeloid-derived suppressor cells (MDSC) by flow cytometry | |
Takao et al. | Flow cytometric quantitation of EpCAM‐positive extracellular vesicles by immunomagnetic separation and phospholipid staining method | |
JP2018021934A (ja) | 腫瘍細胞を検出するためのステロイド受容体アッセイ | |
DiGiuseppe et al. | Immunophenotyping of acute lymphoblastic leukemia | |
Boesch et al. | Harnessing the DNA dye-triggered side population phenotype to detect and purify Cancer stem cells from biological samples | |
US20240053250A1 (en) | Threshold gating for flow cytometry methods | |
Zargaran et al. | Practical 10‐Color T‐Cell Panel for Phenotyping Diverse Populations Using Spectral Flow Cytometry: A Beginner's Guide | |
Fang et al. | Flow Cytometry Applications in the Diagnosis and Classification of Aggressive B-Cell Lymphoma | |
Naicker | Evaluating the Potential of Kode Technology to Attach Nucleic Acids onto Red Cells and Create Reticulocyte Mimics | |
JAMBHULKAR et al. | Multiparameter Flowcytometry for Diagnosis and Subtyping of Mature Lymphocytic Neoplasms in Peripheral Blood and Bone Marrow: A Prospective Observational Study. | |
Bang et al. | Utility of Plasma Cell Screening Tube Kit to Differentiate Neoplastic Plasma Cells from Reactive Plasma Cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150710 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20160512 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160524 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160712 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20161115 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170208 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170404 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170419 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6133297 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |